{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T09:12:10Z","timestamp":1762506730265},"reference-count":21,"publisher":"Japan Endocrine Society","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Endocr J"],"published-print":{"date-parts":[[2016]]},"DOI":"10.1507\/endocrj.ej16-0003","type":"journal-article","created":{"date-parts":[[2016,2,8]],"date-time":"2016-02-08T22:06:33Z","timestamp":1454969193000},"page":"479-484","source":"Crossref","is-referenced-by-count":24,"title":["High serum ALP level is associated with increased risk of denosumab-related hypocalcemia in patients with bone metastases from solid tumors"],"prefix":"10.1507","volume":"63","author":[{"given":"Yuka","family":"Kinoshita","sequence":"first","affiliation":[{"name":"Division of Nephrology & Endocrinology, Department of Medicine, the University of Tokyo Hospital, Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Makoto","family":"Arai","sequence":"additional","affiliation":[{"name":"Division of Nephrology & Endocrinology, Department of Medicine, the University of Tokyo Hospital, Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nobuaki","family":"Ito","sequence":"additional","affiliation":[{"name":"Division of Nephrology & Endocrinology, Department of Medicine, the University of Tokyo Hospital, Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuichi","family":"Takashi","sequence":"additional","affiliation":[{"name":"Fujii Memorial Institute of Medical Sciences, Tokushima University, Tokushima, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Noriko","family":"Makita","sequence":"additional","affiliation":[{"name":"Division of Nephrology & Endocrinology, Department of Medicine, the University of Tokyo Hospital, Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masaomi","family":"Nangaku","sequence":"additional","affiliation":[{"name":"Division of Nephrology & Endocrinology, Department of Medicine, the University of Tokyo Hospital, Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yusuke","family":"Shinoda","sequence":"additional","affiliation":[{"name":"Department of Rehabilitation Medicine, the University of Tokyo Hospital, Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seiji","family":"Fukumoto","sequence":"additional","affiliation":[{"name":"Fujii Memorial Institute of Medical Sciences, Tokushima University, Tokushima, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"386","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Roodman GD (2004) Mechanisms of bone metastasis. <i>N Engl J Med <\/i>350: 1655-1664.","DOI":"10.1056\/NEJMra030831"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Coleman RE (2001) Metastatic bone disease: clinical features, pathophysiology and treatment strategies. <i>Cancer Treat Rev <\/i>27: 165-176.","DOI":"10.1053\/ctrv.2000.0210"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Yamaguchi T, Tamai K, Yamato M, Honma K, Ueda Y, et al. (1996) Intertrabecular pattern of tumors metastatic to bone. <i>Cancer <\/i>78: 1388-1394.","DOI":"10.1002\/(SICI)1097-0142(19961001)78:7<1388::AID-CNCR4>3.0.CO;2-H"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Dougall WC, Chaisson M (2006) The RANK\/RANKL\/OPG triad in cancer-induced bone diseases. <i>Cancer Metastasis Rev <\/i>25: 541-549.","DOI":"10.1007\/s10555-006-9021-3"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Guise TA, Mohammad KS, Clines G, Stebbins EG, Wong DH, et al. (2006) Basic mechanisms responsible for osteolytic and osteoblastic bone metastases. <i>Clin Cancer Res <\/i>12: 6213s-6216s.","DOI":"10.1158\/1078-0432.CCR-06-1007"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Dougall WC, Holen I, Gonzalez Suarez E (2014) Targeting RANKL in metastasis. <i>Bonekey Rep <\/i>3: 519.","DOI":"10.1038\/bonekey.2014.14"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Stopeck AT, Lipton A, Body JJ, Steger GG, Tonkin K, et al. (2010) Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study. <i>J Clin Oncol <\/i>28: 5132-5139.","DOI":"10.1200\/JCO.2010.29.7101"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Fizazi K, Carducci M, Smith M, Damiao R, Brown J, et al. (2011) Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. <i>Lancet <\/i>377: 813-822.","DOI":"10.1016\/S0140-6736(10)62344-6"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Lipton A, Fizazi K, Stopeck AT, Henry DH, Brown JE, et al. (2012) Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: a combined analysis of 3 pivotal, randomised, phase 3 trials. <i>Eur J Cancer <\/i>48: 3082-3092.","DOI":"10.1016\/j.ejca.2012.08.002"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Okada N, Kawazoe K, Teraoka K, Kujime T, Abe M, et al. (2013) Identification of the risk factors associated with hypocalcemia induced by denosumab. <i>Biol Pharm Bull <\/i>36: 1622-1626.","DOI":"10.1248\/bpb.b13-00496"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Ikesue H, Tsuji T, Hata K, Watanabe H, Mishima K, et al. (2014) Time Course of Calcium Concentrations and Risk Factors for Hypocalcemia in Patients Receiving Denosumab for the Treatment of Bone Metastases From Cancer. <i>Ann Pharmacother <\/i>48: 1159-1165.","DOI":"10.1177\/1060028014539919"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Autio KA, Farooki A, Glezerman IG, Chan A, Schneider CW, et al. (2015) Severe Hypocalcemia Associated With Denosumab in Metastatic Castration-Resistant Prostate Cancer: Risk Factors and Precautions for Treating Physicians. <i>Clin Genitourin Cancer <\/i>13: e305-309.","DOI":"10.1016\/j.clgc.2014.11.008"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Body JJ, Bone HG, de Boer RH, Stopeck A, Van Poznak C, et al. (2015) Hypocalcaemia in patients with metastatic bone disease treated with denosumab. <i>Eur J Cancer <\/i>51: 1812-1821.","DOI":"10.1016\/j.ejca.2015.05.016"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Jung K, Lein M (2014) Bone turnover markers in serum and urine as diagnostic, prognostic and monitoring biomarkers of bone metastasis. <i>Biochim Biophys Acta <\/i>1846: 425-438.","DOI":"10.1016\/j.bbcan.2014.09.001"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. de la Piedra C, Alcaraz A, Bellmunt J, Mesequer C, Gomez-Caamano A, et al. (2013) Usefulness of bone turnover markers as predictors of mortality risk, disease progression and skeletal-related events appearance in patients with prostate cancer with bone metastases following treatment with zoledronic acid: TUGAMO study. <i>Br J Cancer <\/i>108: 2565-2572.","DOI":"10.1038\/bjc.2013.270"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Kostenuik PJ, Smith SY, Samadfam R, Jolette J, Zhou L, et al. (2015) Effects of denosumab, alendronate, or denosumab following alendronate on bone turnover, calcium homeostasis, bone mass and bone strength in ovariectomized cynomolgus monkeys. <i>J Bone Miner Res <\/i>30: 657-669.","DOI":"10.1002\/jbmr.2401"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Conill C, Verger E, Salamero M (1990) Performance status assessment in cancer patients. <i>Cancer <\/i>65: 1864-1866.","DOI":"10.1002\/1097-0142(19900415)65:8<1864::AID-CNCR2820650832>3.0.CO;2-U"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Bisballe S, Eriksen EF, Melsen F, Mosekilde L, Sorensen OH, et al. (1991) Osteopenia and osteomalacia after gastrectomy: interrelations between biochemical markers of bone remodelling, vitamin D metabolites, and bone histomorphometry. <i>Gut <\/i>32: 1303-1307.","DOI":"10.1136\/gut.32.11.1303"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Maalouf NM, Heller HJ, Odvina CV, Kim PJ, Sakhaee K (2006) Bisphosphonate-induced hypocalcemia: report of 3 cases and review of literature. <i>Endocr Pract <\/i>12: 48-53.","DOI":"10.4158\/EP.12.1.48"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Rosen CJ, Brown S (2003) Severe hypocalcemia after intravenous bisphosphonate therapy in occult vitamin D deficiency. <i>N Engl J Med<\/i> 348: 1503-1504.","DOI":"10.1056\/NEJM200304103481521"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Holick MF, Binkley NC, Bischoff-Ferrari HA, Gordon CM, Hanley DA, et al. (2011) Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline. <i>J Clin Endocrinol Metab<\/i> 96: 1911-1930.","DOI":"10.1210\/jc.2011-0385"}],"container-title":["Endocrine Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/endocrj\/63\/5\/63_EJ16-0003\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,6,24]],"date-time":"2017-06-24T05:28:44Z","timestamp":1498282124000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/endocrj\/63\/5\/63_EJ16-0003\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016]]},"references-count":21,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2016]]}},"URL":"https:\/\/doi.org\/10.1507\/endocrj.ej16-0003","relation":{},"ISSN":["0918-8959","1348-4540"],"issn-type":[{"value":"0918-8959","type":"print"},{"value":"1348-4540","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016]]}}}